Kristen Oeschlager

Title: Kristen Oeschlager: Innovator in Melanoma Diagnostics

Introduction

Kristen Oeschlager is a prominent inventor based in Phoenix, AZ (US). She has made significant contributions to the field of medical diagnostics, particularly in the area of cutaneous melanoma. With a total of 3 patents to her name, her work is paving the way for advancements in cancer treatment and patient care.

Latest Patents

One of Kristen's latest patents is a diagnostic test for predicting metastasis and recurrence in cutaneous melanoma. This invention encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor. The method involves measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor. It also includes determining a gene-expression profile signature from these levels, comparing the profile to that of a predictive training set, and providing an indication of whether the tumor falls into a certain class of metastasis or treatment risk based on the gene expression profile.

Career Highlights

Kristen Oeschlager is currently associated with Castle Biosciences, Incorporated, where she continues to innovate in the field of diagnostics. Her work is crucial in enhancing the understanding of melanoma and improving patient outcomes through early detection and personalized treatment strategies.

Collaborations

Kristen collaborates with notable professionals in her field, including Robert Willis Cook and Derek Maetzold. These partnerships enhance the research and development efforts at Castle Biosciences, contributing to the advancement of melanoma diagnostics.

Conclusion

Kristen Oeschlager's contributions to melanoma diagnostics exemplify the impact of innovative thinking in medicine. Her patents and ongoing work are vital in the fight against cancer, showcasing the importance of research and collaboration in developing effective diagnostic tools.